Neumora plans NMRA-215 clinical trial in 2026 after favorable toxicology results
NMRA•Preclinical toxicology results support 2026 clinic timeline
- Neumora reported favorable preclinical toxicology results for NMRA-215, supporting plans to move the oral obesity and cardiometabolic drug into the clinic in 2026.
- Results have already been presented; a repeat 13-week rat study showed no unexpected adverse findings, reversing concerns from an earlier study.
- The company kept its timeline to submit an IND in Q4 2026, a key step toward starting human testing.
Related News
BRIEF-Eikon Therapeutics Announces First Patient Dosed In Teluride-008, A Registrational Phase 2/3 Trial Of Eik1001 In Non-Small Cell Lung Cancer
EIKN•
ParaZero, Axon Vision sign MOU to integrate DefendAir net pod with ForceField counter-UAS system
PRZO•
